Saphris is a medicine containing the active ingredient(s) asenapine. On this page you will find out more about Saphris, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: asenapine
Over 65 years of age?
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Saphris 5 mg sublingual wafer, 60
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
SAPHRIS is indicated in the: = treatment of schizophrenia in adults = treatment of acute manic or mixed episodes associated with Bipolar 1 Disorder in adults as monotherapy or in combination with lithium or sodium valproate = prevention of relapse of manic or mixed episodes in Bipolar 1 Disorder in adults as monotherapy or in combination with lithium or sodium valproate.
Table of characteristics
White to off-white, circular wafers, debossed with "5" on one side
Images are the copyright of the Pharmacy Guild of Australia
|Route of administration||Sublingual|
100 tablets: Prescription Only Medicine, or Prescription Animal Remedy
20 tablets: Prescription Only Medicine, or Prescription Animal Remedy
60 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||Store in Original Container,Protect from Light,Protect from Moisture|
|Life time||24 Months|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 February 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
Saphris Wafers - myDr.com.au
Saphris Wafers - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 1 results
Concerns about quetiapine | Issue 3 | Volume 38 | Australian Prescriber
Quetiapine is subsidised by the Pharmaceutical Benefits Scheme to treat schizophrenia and bipolar disorder. An extended-release formulation is also approved...
Read more on Australian Prescriber website